22 March 2017

Services Agreement with QuintilesIMS

Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554

Read more

22 March 2017

Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554

Read more

22 March 2017

Services Agreement with QuintilesIMS

 

Read more

20 March 2017

Posting of Annual report & Notice of AGM

RNS Number : 9721Z

Read more

20 March 2017

2016 Annual Report and Accounts and Notice of AGM

Read more

20 March 2017

Posting of Annual report & Notice of AGM

RNS Number : 9721Z

Read more

2 March 2017

PDMR Dealing

RNS Number : 3484Y

Read more

2 March 2017

PDMR Dealing

RNS Number : 3484Y

Read more

27 February 2017

Final Results

RNS Number : 8595X

Read more

27 February 2017

Final Results

RNS Number : 8595X

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us